StockTipsArenaBeta

BUY Lupin Limited — Somil Mehta, Sharekhan

BUYLupin Limited
Lupin share price target & all analyst calls

bySomil Mehta, SharekhanHorizon: 1–3 months18 Jun 2026via CNBC Awaaz.

Entry₹2,326.9Inferred
Target₹2,430
Total upside +4.43% (call closed)
Stop loss₹2,270-2.45% risk
Exit₹2,43030 Jun 2026, 12:06 pm
Target hit+4.43%0.00%upside left
Follow Somil Mehta for new calls(34% target hit, 77 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 3 active Short-term calls on LUPINSee 45 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 23 Oct, 12:11 am IST
11 supporting0 opposing
Supports the BUY call (11)

Lupin Limited received tentative approval from the U.S. FDA for Enzalutamide Tablets on June 26, 2026. This is a step towards potential market approval.

NSE · Press Release·26 Jun · 4d ago

(opens in new tab)

4 advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·19 Jun · 1w ago

Lupin Ltd has launched Azilsartan Medoxomil Tablets in the United States market.

BSE · Company Update·17 Jun · 2w ago

(opens in new tab)

Lupin Ltd is collaborating with ERN to launch Luforbec (beclometasone/formoterol) pMDI in Spain.

BSE · Company Update·8 Jun · 3w ago

(opens in new tab)

Lupin received approval from the U.S. FDA for Ranluspec (Ranibizumab) Injection.

BSE · Company Update·4 Jun · 4w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Lupin

All analyst calls on Lupin

More from Somil Mehta, Sharekhan

Every call and its outcome